Pharmacy World and Science

, Volume 18, Issue 6, pp 195–203 | Cite as

Developments in antithrombotic therapy: state of the art anno 1996

  • Hugo ten Cate
  • Michael T. Nurmohamed
  • Jan W. ten Cate


This review aims to discuss recent developments in antithrombotic therapy. New and specific inhibitors of platelet dependent thrombosis appear to moderately improve the outcome in coronary vascular disease. Further studies will need to address the cost-benefit ratio of this additional intervention. Hirudin and analogues are potent inhibitors of thrombin, and are clinically efficious, but at current dosage levels still complicated by bleeding. Low molecular weight heparin have markedly improved the efficacy of prevention and treatment of venous thromboembolism.


Antithrombotic drugs Platelet inhibitors Hirudin Low molecular weight heparin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DavieEW, FujikawaK, KisielW. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363–370.Google Scholar
  2. 2.
    tenCateH, LeviM, HackCE. Nieuwe inzichten en hypothesen ten aanzien van de bloedstolling in vivo. Ned Tijdschr Geneeskd 1993;137:282–7.Google Scholar
  3. 3.
    HarkerLA & MannKG. Thrombosis and fibrinolysis. In: FusterV, VerstraeteM (eds) Thrombosis in Cardiovascular Disorders. Philadelphia: W B Saunders, 1992;1–16.Google Scholar
  4. 4.
    HungDT, VuT-K, WheatonVI, et al. 1992 Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992;89:1350–53.Google Scholar
  5. 5.
    HarkerL. Overview of hemostasis. In:ColmanRW, HirshJ, MarderVJ, SalzmanEW (eds) Hemostasis and thrombosis: Basic principles and clinical practice. Third edition. Philadelphia: B Lippincott Company, 1994:3–18.Google Scholar
  6. 6.
    vanZantenGH, deGraafS, SlootwegPJ, HeijnenHFG, ConnollyTM, deGrootPG, SixmaJJ. Increased platelet deposition on antherosclerotic coronary arteries. J Clin Invest 1994;93:615–32.Google Scholar
  7. 7.
    Antiplatelet Trialists' Collaboration 1994 Collaborative overview of randomised trials of antiplatlet therapy-l: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81–106.Google Scholar
  8. 8.
    RothrockJF, HartRG. Ticlopedine hydrochloride use and threatened stroke. West J Med 1994;160:43–7.Google Scholar
  9. 9.
    HarkerLA, MaraganoreJM, Hirsh. Novel antithrombotic agents. In: ColmanRW, HirshJ, MarderVM, SalzmanEW (eds). Hemostasis and Thrombosis: Basic Principles and Clinical practice. Third Edition. Philadelphia: JB Lippincott Company, 1994;1638–60.Google Scholar
  10. 10.
    BellingerDA, NicholsTC, ReadMS, et al. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine vWF 1987 Proc Natl Acad Sci USA 1987;84:8100–4.Google Scholar
  11. 11.
    MillerJL, Thiam-CisseM, DrouetLO. Reduction in thrombus formation by PG-1F(ab')2, an anti-guinea pig platelet glyco-protein lb monoclonal antibody. Arteriosclerosis Thromb 1991;11:1231–6.Google Scholar
  12. 12.
    KrupskiWC, BassA, CadroyY, et al. Antihemostatic and antithrombotic effects of monoclonal antibodies against vWF in nonhuman primates. Surgery 1992;112:433–40.Google Scholar
  13. 13.
    TopolEJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995;75:27B-33B.Google Scholar
  14. 14.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein llb/llla receptor in highrisk coronary angioplasty. New Engl J Med 1994;330:956–61.Google Scholar
  15. 15.
    TopolE, CaliffRM, WeismanHF, et al. Randomised trial of coronary intervention with antibody against platelet IIB/IIIA integrin for reduction of clinical restenosis. Results at six months. Lancet 1994;343:881–6.Google Scholar
  16. 16.
    BoehrerJ D, KereiakesD J, NavettaF I, et al. for the EPIC investigators 1994 Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166–70.Google Scholar
  17. 17.
    TchengJE, HarringtonRA, Kottke-MarehoutK, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIB/IIIA blocker integrelin in elective coronary intervention. Circulation 1995; 91:2151–7.Google Scholar
  18. 18.
    SimoonsML, deBoerJM, BrandM, et al. Randomized trial of a Gpllb/llla platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596–603.Google Scholar
  19. 19.
    Theroux P, White H, David D, et al. A heparin-controlled study of MK-393 in unstable angina. Circulation 1994. Abstract.Google Scholar
  20. 20.
    NicholsonNS, Panzer-KnodleSG, SalyersAK, et al. SC-54684A: An orally active inhibitor of platelet aggregation. Circulation 1995;91:403–10.Google Scholar
  21. 21.
    NicoliniFA, LeeP, RiosG, et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802–9.Google Scholar
  22. 22.
    FitzGeraldGA & OatesJA. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35:633–40.Google Scholar
  23. 23.
    ReillyIAG & FitzGeraldGA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;69:180–6.Google Scholar
  24. 24.
    MorioH, HiraiA, TeranoT, et al. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Thromb Haemostas 1993;69:276–81.Google Scholar
  25. 25.
    The RAPT investigators. Randomized trial of Ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandinendoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 1993;89:588–95.Google Scholar
  26. 26.
    SchumacherWA, HeranCL, SteinbacherTE, et al. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. J Cardiovasc Pharmacol 1993;22:526–33.Google Scholar
  27. 27.
    WilsonHC, CoffmanW, KillamAL, CohenML. Ly 53587, a 5-HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion. Thomb Haemostas 1991;66:355–60.Google Scholar
  28. 28.
    HaraH, KitajimaA, ShimadaH, TamaoY. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemostas 1991;66:484–88.Google Scholar
  29. 29.
    HerbertJM, BernatA, BarthelemyG, et al. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemostas 1993;69:262–267.Google Scholar
  30. 30.
    CookJJ, SitkoGR, BednarB, CondraC, MellotMJ, FengDM, et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the african green monkey. Circulation 1995;91:2961–71.Google Scholar
  31. 31.
    GachetC, StierleA, CazenaveJ-P, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990;40:229–38.Google Scholar
  32. 32.
    SaviP, BernatA, DumasA, et al. Effect of aspirin and clopidogrel on platelet-depen dent tissue factor expression in endothelial cells. Thromb Res 1994;73:117–24.Google Scholar
  33. 33.
    MaffrandJP, BernatA, DelebasseeD, et al. ADP plays a key role in thrombogenesis in rats. Thromb Haemostas 1988;59:225–30.Google Scholar
  34. 34.
    MarkwardtF. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1–23.Google Scholar
  35. 35.
    MaraganoreJM, BourdonP, JablonskiJ, et al. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochem 1990;29:7095-?Google Scholar
  36. 36.
    Skrzypczak-Jankun, CarperosVE, RavichandranKG, et al. Structure of hirugen and hirulog 1 complexes of α-thrombin. J Mol Biol 1991;221:1379–93.Google Scholar
  37. 37.
    MarbetGA, VerstraeteM, KienastJ, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364–72.Google Scholar
  38. 38.
    FoxI, DawsonA, LoyndsP, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemostas 1993;69:157–63.Google Scholar
  39. 39.
    van denBosAA, DeckersJW, HeyndrickxGR, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993;88:2058–66.Google Scholar
  40. 40.
    TopolEJ, FusterV, HarringtonRA, et al. Recombinant hirudin for unstable angina pectoris. Circulation 1994;89: 1557–66.Google Scholar
  41. 41.
    BittlFA, StronyJ, BrinkerJA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Eng J Med 1995; 333:764–69.Google Scholar
  42. 42.
    CannonCP, McCabeCH, HenryTD, et al. A pilot trial of recombinant desulfato-hirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23:993–1003.Google Scholar
  43. 43.
    The global use of strategies to open occluded coronary arteries (GUSTO) IIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631–7.Google Scholar
  44. 44.
    AntmanEM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Circulation 1994;90:1624–30.Google Scholar
  45. 45.
    NeuhausKL, vonEssenR, TebbeU, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994;90:1638–42.Google Scholar
  46. 46.
    LidonR-M, TherouxP, LesperanceJ, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567–72.Google Scholar
  47. 47.
    ErikssonBI, KäleboP, Ekman et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemostas 1994;72:227–31.Google Scholar
  48. 48.
    ErikssonBI, KäleboP, Ekman et al. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin CGP 39393 (RevascR), Ciba, compared to unfractionated heparin. Circulation 1994;90:I-569.Google Scholar
  49. 49.
    EkmanS, ErikssonBI, LindbrattS, et al. Recombinant hirudin, CGP 39393 15 mg (TMRevasc-Ciba), is the most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Thromb Haemostas 1995;73:1093.Google Scholar
  50. 50.
    ParentF, BrideyF, DreyfusM, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemostas 1993;70:386–8.Google Scholar
  51. 51.
    SchieleF, VuillemenotA, KramarzPh, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemostas 1994;71:558–62.Google Scholar
  52. 52.
    GinsbergJS, NurmohamedMT, GentM, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90:2385–9.Google Scholar
  53. 53.
    BodeC, HudelmayerM, MehwaldP, et al. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficientl than recombinant hirudin. Circalation 1994;90:1956–63.Google Scholar
  54. 54.
    MeyerBL, Fernandez-OrtizA, MailhacA, et al. Local delivery of r-hirudin by a double balloon perfusion cathter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994;90:2474–80.Google Scholar
  55. 55.
    RirshJ & LevineMN. Low molecular weight heparin. Blood 1992;79:1–17.Google Scholar
  56. 56.
    AnderssonLO, BarrowcliffeTW, HolmerE, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979;15:531–41.Google Scholar
  57. 57.
    NurmohamedMT, RoosendaalFR, BullerHR, et al. Lowmolecular weight heparin in general and orthopedic surgery: a meta analysis. Lancet 1992;340:152–6.Google Scholar
  58. 58.
    LeizoroviczA, SimonneauG, DecoususH, BoisselJP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. Br Med J 1994; 309:299–304.Google Scholar
  59. 59.
    JorgensenLN, Wille-JorgensenP, HauchO. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993;80:689–704.Google Scholar
  60. 60.
    LeizoroviczA, HaughMC, ChapuisF-R, et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992;305:913–20.Google Scholar
  61. 61.
    LensingAWA, PrinsMH, DavidsonBL, et al. Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med 1995;155:601–7.Google Scholar
  62. 62.
    KoopmanMMW, PrandoniP, PiovellaF, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular-weight heparin administered at home. N Engl J Med 1996;334:682–7.Google Scholar
  63. 63.
    LevineM, GentM, HirshJ, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractioned heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677–81.Google Scholar
  64. 64.
    NurmohamedMT, tenCateJ, StevensP, et al. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans 1991;37:M459–61.Google Scholar
  65. 65.
    NurmohamedMT, BüllerHR, tenCateJW. Low molecular weight heparins in extracorporeal circuits. In: BounameauxH, ed. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases. Marcel Dekker Inc, New York: 1994;247–71.Google Scholar
  66. 66.
    AsterRH. Heparin induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374–6.Google Scholar
  67. 67.
    NurmohamedMT, vanRielAM, HenkensCMA, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemostas 1996;75:233–8.Google Scholar
  68. 68.
    KayR, WongKA, YuYL, et al. Low molecular weight heparin for the prevention of acute ischemic stroke. N Engl J Med 1995;333:1588–93.Google Scholar
  69. 69.
    tenCateH, HennyCP, tenCateJW, BullerHR. Clinical studies with low-molecular-weight heparin(oid)s: an interim analysis. Am J Hematol 1988;27:146–53.Google Scholar
  70. 70.
    tenCateH, HennyCP, tenCateJW, et al. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemostas 1987;57:92–6.Google Scholar
  71. 71.
    Bachmann F en Leyvraz PF. LMWH after orthopeadic surgery. In: Bounameaux H, ed. Low molecular weight heparins in prophylaxis and therapy of thromboembolic dis eases. Thromb Haemostas 1987;57:92–6.Google Scholar
  72. 72.
    MasseyEW, BillerJ, DavisJN, et al. Large-dose infusion of heparinoid Org 10172 in ischemic stroke. Stroke 1990; 21: 1289–92.Google Scholar
  73. 73.
    MagnaniHN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 1993;70:554–61.Google Scholar
  74. 74.
    BuchwaldAB, UnterbergC, NebendahlK, et al. Low-molecular weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Clrculation 1992;86:531–7.Google Scholar
  75. 75.
    FernandezF, VanRijnJ, OfosuFA, et al. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986;64:309–17.Google Scholar
  76. 76.
    HoppensteadtD, WalengaJM, FareedJ. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 1990;60:191–200.Google Scholar
  77. 77.
    AgnelliG, CosmiB, DiFilippoP, et al. A randomized, double blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 1992;67:203–8.Google Scholar
  78. 78.
    BrandoniP, MeduriF, CuppiniS, et al. Dermatan sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992;79:505–9.Google Scholar
  79. 79.
    NurmohamedMT, KnipscheerHC, StevensP, et al. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients. Clin Nephrol 1993;39:166–71.Google Scholar
  80. 80.
    CosmiB, AgnelliG, YoungE, et al. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. Thromb Haemostas 1993;70:443–7.Google Scholar
  81. 81.
    OlsonST, BjorkI, ShefferR, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. J Biol Chem 1992;267: 12528–38.Google Scholar
  82. 82.
    Walenga JM, Petitou M, Lormeau JC, et al. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 197 46:187–98.Google Scholar
  83. 83.
    CarrieD, CaranobeC, SaivinS, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin IIl in the rabbit: comparison with CY 216. Blood 1994;84:2571–7.Google Scholar
  84. 84.
    VogelGMT, vanAmsterdamRGM, KopWJ, MeulemanDG. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemostas 1993;69:29–34.Google Scholar
  85. 85.
    LeviM, tenCateH, BauerKA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114–20.Google Scholar
  86. 86.
    BiemondBJ, LeviM, tenCateH, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemostas 1995;73:223–30.Google Scholar
  87. 87.
    TaylorFBJr. Role of tissue factor in the coagulant and inflammatory response to LD100E. coli sepsis and in the early diagnosis of DIC in the baboon. In: BerghausGM, MadlenerK, BlombackM, tenCateJW (eds.) DIC. Pathogenesis, diagnosis and therapy of disseminated intravascular fibrin formation. Amsterdam: Excerpta Medica 1993;19–31.Google Scholar
  88. 88.
    CreaseyAA, ChangACK, FeigenL, et al. Tissue factor pathway inhibitor reduces mortality fromEscherichia coli septic shock. J Clin Invest 1993;91:2850–60.Google Scholar
  89. 89.
    WunT-C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 1992;79:430–8.Google Scholar
  90. 90.
    AbendscheinDR, MengYY, Torr BrownS, SobelBE. Maintenance of coronary patency after fibrinolysis, with tissue factor pathyway inhibitor. Circulation 1995;92:944–9.Google Scholar
  91. 91.
    HaskelEJ, TorrSR, DayKC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84:821–7.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Hugo ten Cate
    • 1
  • Michael T. Nurmohamed
    • 1
  • Jan W. ten Cate
    • 2
  1. 1.Dept of Internal MedicineSlotervaart HospitalAmsterdamThe Netherlands
  2. 2.Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation ResearchAcademic Medical CentreAmsterdamThe Netherlands

Personalised recommendations